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Abstract
A new optimal control model of the interactions between a growing
tumour and the host immune system along with an immunotherapy
treatment strategy is presented. The model is based on an ordinary
differential equation model of interactions between the growing tu-
mour and the natural killer, cytotoxic T lymphocyte and dendritic
cells of the host immune system, extended through the addition of a
control function representing the application of a dendritic cell treat-
ment to the system. The numerical solution of this model, obtained
from a multi species Runge–Kutta forward-backward sweep scheme,
is described. We investigate the effects of varying the maximum al-
lowed amount of dendritic cell vaccine administered to the system and
find that control of the tumour cell population is best effected via a
high initial vaccine level, followed by reduced treatment and finally
cessation of treatment. We also found that increasing the strength of
the dendritic cell vaccine causes an increase in the number of natural
killer cells and lymphocytes, which in turn reduces the growth of the
tumour.
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1 Introduction and background
We study an optimal control treatment strategy for the interactions between
a growing tumour and the host immune system. The numerical solution of
the model is obtained from a Runge–Kutta forward-backward sweep scheme.
An optimal control model is developed by building on an ordinary differential
equation (ode) model of tumour-immune system interactions through the
addition of a control function, u, representing the application of a dendritic
cell treatment.
Extensive mathematical research has been undertaken into the growth
of tumour cell colonies. Of particular interest here is the body of research
related to the modelling of tumour interactions with the immune system and
treatment using immunotherapy (for example [1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12,
13, 17]. Kirschner and Panetta [13] illustrated the effect of adoptive cellular
immunotherapy through a mathematical model which consists of tumour
cells, immune-effector cells and interleukin-2. This model describes under
what conditions the tumour is destroyed as a result of the therapy. De Pillis et
al. [6] developed a mathematical model describing the growing tumour with
combination immune, vaccine and chemotherapy treatments. In addition,
Capppucio et al. [3] introduced a mathematical model of tumour immune
system interactions focusing on natural killer (nk) and T cell immunity,
combined with interleukin-21 as an immunotherapy. However, there are very
few models which study the effect of dendritic cell (dc) vaccines on a growing
tumour (for example [5]) and these treat the immune system in a different
manner to the presented research.
Optimal control theory is a commonly employed strategy to determine a
treatment method that guarantees a minimum of some cost (such as monetary
costs or harm to the patient) while minimising the tumour cell population (see
for example [2, 9, 10, 11, 19, 21] and the review by Swan [20]). Chemotherapy
is commonly studied as the tumour treatment, while immune cell treatment
(see for example [2, 11]) is more rarely investigated.
Of particular relevance here is the work of Castiglione and Piccoli [5],
who constructed a mathematical model to describe the interaction between
immune system cells and tumour cells. They then applied optimal control
methods to find the optimal quantity of dendritic cells to be administered
to the tumour site. In the current research, we also focus on dc-based im-
2 Mathematical model 3
munotherapeutic treatment, however our work is different from Castiglione
and Piccoli’s since we include nk cells and also describe in more detail the
role of dendritic cells in tumour control.
In the following section we present an ode model of tumour cell inter-
actions with specific components of the immune system, that incorporates
a time-varying dendritic cell-based treatment strategy and also an objective
functional that we seek to minimise. We then discuss the numerical scheme
itself, a multispecies forward-backward sweep method using a Runge–Kutta
ode solver and present a number of important numerical solutions of the
optimal control model. Finally, we discuss the results of the model in the
context of the tumour growth problem.
2 Mathematical model
To describe the interactions between the growing population of tumour cells
and specific components of the immune system, we introduce four cell species,
namely the concentrations of tumour cells, denoted T (t), nk cells, N(t),
dendritic cells, D(t), and cd8+ T cells (cluster of differentiation 8), L(t),
where here t is time.
We assume that the growth of the tumour cell population is logistic,
while tumour cells are removed due to interactions with nk, dendritic and
cd8+ T cells [15]. nk cells and dcs are normally present in the body, even
when no tumour cells are present. After some number of interactions with
tumour cells, nk cells and cd8+ T cells become inactive and are removed
from consideration. dcs are able to prime the activity of nk cells and cd8+
T cells [18]. Finally, mature cd8+ T cells can clear out dendritic cells [5,
22]. Combining these assumptions, we model the tumour-immune system
interactions using the system of odes
dT
dt
= aT (1− bT )− (c1N + jD + kL)T, (1)
dN
dt
= s1 − c2NT + d11 DN
m1 +D
− eN, (2)
dD
dt
= s2 + l
DT
m2 + T
− f1LD − d2DN − gD, (3)
dL
dt
= f22
DT
m3 + T
− hLT − iL, (4)
where the parameters are described, along with estimated values and litera-
ture sources, in Table 1.
2 Mathematical model 4
Param. Description Value Source
a Tumour growth rate 4.31× 10−1 [6]
b b−1 tumour carrying capacity 2.17× 10−8 [6]
c1 nk cell tumour cell kill rate 3.5× 10−6 [8]
c2 nk cell inactivation rate by tumour cells 1.0× 10−7 [6]
d11 Maximum rate of nk cell activation 5.0× 10−2 Est.
d2 nk cell dendritic cell kill rate 4.0× 10−6 Est.
e Death rate of nk cell 4.12× 10−2 [14]
f1 CD8
+T cell dendritic cell kill rate 1.0× 10−8 [5]
f22 Maximum rate of cd8
+ T cell activation 1.0× 10−2 Est.
g Death rate of dendritic cell 2.4× 10−2 [22]
h CD8+T inactivation rate by tumour cells 3.4× 10−10 [6]
i Death rate of CD8+T cells 2.0× 10−2 [6]
j Dendritic cell tumour cell kill rate 1.0× 10−2 Est.
s1 Source of nk cells 1.3× 104 [14]
s2 Source of dendritic cells 4.8× 102 [22]
l Max. dc recruitment by tumour cells 1.0× 10−2 Est.
m1 nk cell activation rate steepness coeff. 1.0× 104 Est.
m2 Tumour cell recruitment steepness coeff. 1.0× 104 Est.
m3 cd8
+ T cell activation steepness coeff. 3.0× 103 Est.
Table 1: Parameters, values and sources, used in the solution of the model
given by equations (1)–(4).
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We introduce the function u(t) ≥ 0 to represent the dendritic cell vaccine
treatment rate. Positive values of u(t) correspond with an influx of dcs
supplied from outside the system. Hence, equation (3) becomes
dD
dt
= s2 + l
DT
m2 + T
− f1LD − d2DN − gD + u (t) . (5)
We now introduce an objective functional as part of the optimal control
problem. We aim to minimise the tumour burden over the length of time
modelled, and also the ‘cost’ of the treatment (be it harm to the patient, cost
to administer treatment, or some other interpretation – here we adopt the
u2 form employed in similar works [6]). Hence we aim to minimise J [t, u(t)],
where
J [t, u(t)] =
∫ tf
0
(
T (t) +
B
2
u2(t)
)
dt, (6)
where tf is the specified final time and B is a weighting factor that represents
the relative importance of the cost as opposed to the tumour burden, in the
minimisation problem. In the simulations, we used B = 10−3, reflecting the
relatively higher importance placed on reducing the tumour burden than on
the cost of the treatment.
3 Computational implementation
To proceed with the solution of the optimal control problem, we first rewrite
our system as follows. We seek to solve
x′(t) = g(t,x, u), (7)
where x(t) = [T (t), N(t), D(t), L(t)]T is the vector of solutions of the state
equations (1), (2), (5) and (4), and g is the vector of right hand sides of the
state equations. Also, we rewrite equation (6) as
J(t,x(t), u(t)) =
∫ tf
0
f(t,x, u) dt, (8)
where f is the integrand of equation (6).
Next, we form the Hamiltonian function
H(t,x, u, λ) = f(t,x, u) + λTg(t,x, u).
where λ is the vector of adjoint functions. Then we have the optimality
condition
∂H
∂u
= 0 at u∗ ⇒ fu + λTgu = 0,
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as well as the adjoint equation and transversality condition
λ′ = −∂H
∂x
= −(fx + λTgx), λ(tf) = 0. (9)
We now present the algorithm (the forward-backward sweep method)
used to solve the bounded optimal control problem of Section 2. We out-
line an adapted version of the single equation scheme presented in Lenhart
and Workman [16] that allows us to solve the multispecies optimal control
problem.
Consider the optimal control problem
min
u
∫ tf
t0
f(t,x(t), u(t)) dt,
subject to x′ = g(t,x(t), u(t)), x(t0) = x0,
where x ∈ Rn×1, u ∈ R, and n is the number of state equations. Let
X ∈ Rn×(N+1), Λ ∈ Rn×(N+1), U ∈ RN+1, where N + 1 is the number
of time steps to be taken, X is the approximation to x at the N + 1 time
steps, and Λ is a matrix of the adjoint equations. Then to solve the optimal
control problem:
1. Discretise the time domain into N + 1 equidistant mesh points t1,
t2, . . . , tN+1.
2. Make an initial guess U for u over the interval.
3. Using the initial condition Xi,1 = x0, i = 1, . . . , N + 1, and U, solve
equation (7) forward in time using the order four Runge–Kutta method
to obtain the next approximation for X.
4. Using the transversality condition Λi,N+1 = λ(tf ) = 0 and the values
for U and X, solve equation (9) backward in time to obtain the next
approximation for Λ.
5. Update U. If values of U at this iteration and the last are not suffi-
ciently close, return to step 3 using the updated X and Λ values. If
values are sufficiently close, then the control is optimal: output X and
U as approximations to x and u.
4 Results
In this section, the optimal control problem set up in Section 2 is solved using
the forward-backward sweep method as discussed in Section 3.
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Figure 1: Tumour cell population evolution using a large initial tumour cell
population, showing the growth with no dc treatment (dashed) and the
impact of the dc based vaccine (solid).
Figure 2: The optimal control, u, used for solutions in Figure 1.
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Figure 3: Impact of the dc vaccine on nk cell evolution for maximum vac-
cine levels umax = 2 (solid), 20 (dashed) and 200 (dotted). Increasing umax
increases the peak nk level and decreases the time to reach that peak.
In Figure 1 we show a plot of the tumour cell population using a large
initial value of tumour cells, demonstrating the impact of the dc vaccine-
based control strategy. The dashed line shows the tumour population growth
resulting from no control, while the solid line (more easily seen inset) shows
the tumour cell population eradication resulting from the optimal control
vaccine strategy. With the initial value T0 = 5 × 104 cells, without vaccine,
tumour cells grow to the nonzero tumour equilibrium after around 120 days.
However, the tumour is eliminated in just under 40 days using the optimal
control strategy. The inset plot shows that the tumour cell population is
completely removed within 40 days whereas without control, the number
of tumour cells remains high at this time. The dendritic cell vaccine to
be administered during this treatment is seen in Figure 2. To eliminate the
tumour cells as shown in Figure 1, the maximum vaccine treatment should be
administered for approximately the first 58 days, after which the treatment
reduces sharply and finally stops at day 62.
Increasing the strength of the dc vaccine not only impacts the tumour cell
population, it also causes increases in the numbers of nk cells (see Figure 3)
and cd8+ T cells (see Figure 4). These effects in turn reduce the tumour cell
population as shown in Figure 5. The effect is very significant in increasing
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Figure 4: Impact of the dc vaccine on cd8+ T cell evolution for maximum
vaccine levels umax = 2 (solid), 20 (dashed) and 200 (dotted). Increasing
umax increases the peak cd8
+ T cell level and decreases the time to reach
that peak.
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Figure 5: Impact of the dc vaccine on the tumour cell evolution for maximum
vaccine levels umax = 2 (solid), 20 (dashed) and 200 (dotted). Increasing umax
decreases the peak tumour cell level and the time to reach that peak.
the number of cd8+ T cells, consequently reducing the tumour burden. This
particular numerical solution shows that dcs alter the population of cd8+
T cells much more than nk cells.
5 Discussion
We have presented a new optimal control model of dendritic cell treatment
of a growing population of tumour cells. The model builds on the previous
modelling literature in terms of the type of model and the optimal control
approach, but differs from existing work through the explicit treatment of
dcs in addition to nk and cd8+ T cells. The model was solved using a mul-
tispecies implementation of the forward-backward sweep method for solving
optimally controlled systems of odes.
Our results focus on investigating the effects of varying the maximum
allowed amount of dc vaccine administered to the system. We found that
the best way to control the tumour cell population is to give a high vaccine
level at the beginning of the treatment and then reduce the treatment after
a specific period of time, determined as part of the solution of the optimal
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control problem. We also found that increasing the strength of the dc vaccine
causes an increase in the number of nk cells and cd8+ T cells, which in turn
reduces the growth of the tumour. Increasing the strength of the dc vaccine
also reduces the required duration of the treatment.
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